See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive answer to whether Cosentyx (secukinumab) alters inactivated vaccine protection. However, it is known that certain biologic medications, including some used to treat autoimmune conditions like Cosentyx, can impact the immune system's response to vaccines.

Cosentyx is a monoclonal antibody that specifically targets interleukin-17A (IL-17A), a cytokine involved in inflammatory and immune responses. By inhibiting IL-17A, Cosentyx helps reduce inflammation and symptoms in conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

According to DrugPatentWatch.com, there are currently no patents directly related to the use of Cosentyx in combination with inactivated vaccines [2]. However, this does not provide information on the interaction between Cosentyx and inactivated vaccines.

The impact of biologic therapies on vaccine response may vary depending on the specific medication and vaccine type. For instance, a study published in the Journal of Allergy and Clinical Immunology found that TNF-alpha inhibitors, another class of biologics, can impair the immune response to certain vaccines [3].

Given the limited information available specifically regarding Cosentyx and inactivated vaccine protection, it is recommended that patients consult their healthcare providers for personalized advice. Healthcare providers can consider factors such as the patient's medical history, current treatment plan, and the specific vaccine in question when determining the best course of action [4].

In summary, while there is no direct evidence on Cosentyx altering inactivated vaccine protection, biologic medications like Cosentyx can impact the immune system's response to vaccines. Patients should consult their healthcare providers for personalized advice on vaccine administration and potential interactions with Cosentyx.

Sources:
[1] Novartis. (2021). Cosentyx (secukinumab). Retrieved from <https://www.novartis.com/our-work/therapeutic-areas/immuno-dermatology/cosentyx>
[2] DrugPatentWatch.com. (2022). Secukinumab. Retrieved from <https://www.drugpatentwatch.com/drugs/secukinumab>
[3] Ziv, Y., Atkinson, J. P., & Ballow, M. (2014). Impact of biologic agents on immune responses to vaccines. Journal of Allergy and Clinical Immunology, 133(2), 321-331. doi: 10.1016/j.jaci.2013.11.021
[4] Centers for Disease Control and Prevention. (2021). Recommendations of the Advisory Committee on Immunization Practices (ACIP) for Use of COVID-19 Vaccines | CDC. Retrieved from <https://www.cdc.gov/vaccines/acip/recommendations/covid-19/covid19-vaccines.html>